Literature DB >> 34326955

Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus.

Shuai Wang1, Hui Yong1, Xiao-Dong He2.   

Abstract

Type 2 diabetes mellitus (T2DM) is a burdensome global disease. In-depth understanding of its mechanism will help to optimize diagnosis and treatment, which reduces the burden. Multi-omics research has unparalleled advantages in contributing to the overall understanding of the mechanism of this chronic metabolic disease. In the past two decades, the study of multi-omics on T2DM-related intestinal flora perturbation and plasma dyslipidemia has shown tremendous potential and is expected to achieve major breakthroughs. The regulation of intestinal flora in diabetic patients has been confirmed by multiple studies. The use of metagenomics, 16S RNA sequencing, and metabolomics has comprehensively identified the overall changes in the intestinal flora and the metabolic disturbances that could directly or indirectly participate in the intestinal flora-host interactions. Lipidomics combined with other "omics" has characterized lipid metabolism disorders in T2DM. The combined application and cross-validation of multi-omics can screen for dysregulation in T2DM, which will provide immense opportunities to understand the mechanisms behind T2DM. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemias; Gastrointestinal microbiome; Intestinal flora; Lipid metabolism disorders; Metabolomics; Type 2 diabetes mellitus

Year:  2021        PMID: 34326955      PMCID: PMC8311486          DOI: 10.4239/wjd.v12.i7.1070

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


Core Tip: The prospects of multi-omics in the study of the mechanisms of type 2 diabetes mellitus (T2DM)-related intestinal flora perturbation and plasma dyslipidemia are tremendous. The use of multi-omics has identified variations in T2DM intestinal flora composition and human-microbiota interactions. However, further sequencing is required, and the clinical application needs to be clarified and simplified. Multi-omics is also identifying T2DM lipid profiles, which will provide immense opportunities to understand the mechanisms of T2DM-related dyslipidemia.

INTRODUCTION

According to the World Health Organization, about 422 million people worldwide have diabetes and 1.6 million deaths are directly attributed to diabetes each year. Diabetes is a chronic, metabolic disease characterized by elevated blood glucose (or blood sugar) levels, which increases morbidity and mortality. When the body does not produce enough insulin or does not use it efficiently, diabetes manifests. The number of patients with diabetes is increasing, which expands the magnitude of the disease burden[1]. The most common type of diabetes is type 2 diabetes mellitus (T2DM)[2]. When genetics, age, and family history are fixed, reducing exposure to other known risk factors for T2DM using a variety of interventions and improving access to and quality of care decrease the incidence of T2DM and benefit patients with T2DM[3]. The effectiveness of these interventions depends largely on the understanding of the mechanism of T2DM. Due to the complexity of the mechanisms and causes of T2DM, traditional bench science has limitations. Multi-omics, including genomics, transcriptomics, proteomics, glycomics, metabolomics, epigenomics, ncRNomics, lipidomics, and interactomics, offers a fresh and exciting conceptual lens that will aid scientists to comprehensively and systematically understand the physiological processes and regulatory mechanisms of T2DM[4].

ADVANTAGES OF MULTI-OMICS ON STUDY OF MECHANISM OF T2DM

Since the concept of genomes and genomics was introduced, “omics” research has profoundly affected systems biology discoveries. Multi-omics research enables researchers to identify the differences in genes, proteins, and metabolites that lead to understanding overall functional disturbances in diseases, including T2DM. Using multi-omics, our previous research[5,6] described the intestinal flora alterations and the plasma protein metabolic profile perturbations in the Zucker diabetic fatty rat, which is a spontaneous T2DM animal model commonly used to develop drugs for treating diabetes[7-10]. The altered intestinal microbiota and differentially expressed proteins and metabolites clearly distinguished the treatment group [T: Zucker leptin receptor gene-deficient rats (fa/fa) treated by Purina #5008] from the control group [C: basic diet-fed litter mate wild-type controls (fa/+)]. This provided an important reference for screening and verifying T2DM by utilizing intestinal flora and plasma biomarkers. Using “omics” techniques, the increased levels of glycated hemoglobin, ceruloplasmin, triacylglycerols, diacylglycerols, phosphatidylethanolamines, etc. in plasma/urine have been verified in the human population. They are gradually being introduced in the early diagnosis of diabetes and the prediction of serious adverse complications[11-13]. Further functional analysis of the differential molecules using multi-omics revealed the pathophysiological mechanism of T2DM (Figure 1). The intestinal flora and the host exhibit similar features that focus on oxidative stress, insulin resistance, and metabolic disorders. This data confirmed previous T2DM mechanism research[14-16] and provided insight into the overall levels of molecules.
Figure 1

Multi-omics verification of the mechanism of type 2 diabetes mellitus. A: Schematic diagram of multi-omics verification; B: Conceptual diagram of the Zucker diabetic fatty rat modeling process; C: Body weight (left) and blood sugar (right) before and after basic diet feeding in B; D: Fecal 16S rRNA sequencing biomarkers; E: Genomic functions of the disturbed intestinal flora; F: Overview of the complete metabolism in the two biological system; G: Protein-protein interaction network of plasma differentially expressed proteins (DEPs); H: Functional enrichment of DEPs; I: Visualization of G and H. The cross-validation of intestinal flora and the plasma proteome further emphasizes that oxidative stress, insulin resistance, energy intake and consumption imbalances, and lipid metabolism disorders play an important part in the occurrence of type 2 diabetes mellitus (T2DM). Dyslipidemia may be a major hub for the in vivo and in vitro changes in T2DM (unpublished data). The data used in the figure are our published and public data in open access journals, which are displayed after further analysis. C and G: Citation: Wang S, Lu Z, Wang Y, Zhang T, He X. Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats. Nutr Metab (Lond) 2020; 17: 66. Copyright ©The Author(s) 2020. Published by Springer Nature[6]. T: Zucker leptin receptor gene-deficient rats (fa/fa) treated by Purina #5008 for 3 wk; C: Basic diet-fed litter mate wild-type controls (fa/+); DEPs: Differentially expressed proteins; T2DM: Type 2 diabetes mellitus.

Multi-omics verification of the mechanism of type 2 diabetes mellitus. A: Schematic diagram of multi-omics verification; B: Conceptual diagram of the Zucker diabetic fatty rat modeling process; C: Body weight (left) and blood sugar (right) before and after basic diet feeding in B; D: Fecal 16S rRNA sequencing biomarkers; E: Genomic functions of the disturbed intestinal flora; F: Overview of the complete metabolism in the two biological system; G: Protein-protein interaction network of plasma differentially expressed proteins (DEPs); H: Functional enrichment of DEPs; I: Visualization of G and H. The cross-validation of intestinal flora and the plasma proteome further emphasizes that oxidative stress, insulin resistance, energy intake and consumption imbalances, and lipid metabolism disorders play an important part in the occurrence of type 2 diabetes mellitus (T2DM). Dyslipidemia may be a major hub for the in vivo and in vitro changes in T2DM (unpublished data). The data used in the figure are our published and public data in open access journals, which are displayed after further analysis. C and G: Citation: Wang S, Lu Z, Wang Y, Zhang T, He X. Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats. Nutr Metab (Lond) 2020; 17: 66. Copyright ©The Author(s) 2020. Published by Springer Nature[6]. T: Zucker leptin receptor gene-deficient rats (fa/fa) treated by Purina #5008 for 3 wk; C: Basic diet-fed litter mate wild-type controls (fa/+); DEPs: Differentially expressed proteins; T2DM: Type 2 diabetes mellitus.

MULTI-OMICS AND T2DM-RELATED INTESTINAL FLORA DISTURBANCE

Multi-omics aided the dramatic discovery that diabetes was associated with the intestinal flora. The altered microbiota observed in genetically obese mice[17] or people[18-20] is sufficient to promote increased adiposity in lean mice that receive a microbiota transplant. Germ-free mice, which lack a microbiota, have reduced adiposity and improved tolerance to glucose and insulin when compared to their counterparts[21]. They are also free from diet-induced obesity when fed a Western-style diet[22-24]. Taken together, the correlation between intestinal flora, obesity, and diabetes demonstrates that the microbiota contributes to the regulation of adiposity and T2DM[25]. However, the precise mechanism is still not clear. Increased metagenomics data (usually 16S RNA sequencing) suggest that the extent of biodiversity within an ecosystem can be an important mechanism and serve as a measure of stability and robustness. In other words, a reduction in gut microbiome diversity and richness is linked to susceptibility to T2DM[26,27]. The complex composition of the intestinal flora can quickly change in response to a diverse diet, while simpler flora composition can only interact with specific diets and increase the vulnerability of the intestinal tract[28]. In T2DM rats and patients, the proportion of Firmicutes decreased and that of Bacteroidetes increased[29]. This ratio can be used as a simple indicator of intestinal flora diversity in T2DM. Although metagenomics has an irreplaceable advantage in T2DM-related intestinal flora studies, sequencing depth and defects in methods still need to be paid more attention. 16S RNA sequencing enables taxonomic identification to at least the family level but is rarely able to make a distinction between different strains of the same species or related species[30]. Salmonella, Escherichia coli, and Shigella would be identified by the same sequence, yet their significance in T2DM may vary. Although the intestinal flora ratios may be important, the metabolic function of the intestinal flora on nutrients and food likely plays a more significant role[31,32]. Metabolites of the intestinal flora are involved in numerous functions. They can affect the absorption of nutrients (bile acid metabolism is closely related to lipid absorption[33,34]), and they can be absorbed to provide nutrients for the host (carbohydrates are fermented to form short-chain fatty acids to provide energy for the host[35-37]). Metabolites can be signaling molecules to regulate inflammation and immunity inter- or intra-intestinally. Bacterial L-tryptophan metabolites enhance the secretion of glucagon-like peptide-1[38-40]. Endotoxins (lipopolysaccharides) induce inflammation[41] and limit the autoimmune response[42,43]. Many metabolites produced due to the interaction of numerous species, the allocation of resources, and the dynamic response to perturbation within the gut may serve as potential T2DM biomarkers[44]. Table 1 briefly summarizes related gut microbiota metabolites and their interactions with the host in diabetes. The complementation of intestinal metabolomics and metagenomics will enhance the research on T2DM-related intestinal flora disturbance[45].
Table 1

Intestinal flora-related metabolites and their host interaction mechanism

Metabolites
Potential interaction mechanism between intestinal flora-related metabolites and the host
Bile acidsPromotes fat absorption; serves as signaling molecule [acts with G-protein-coupled bile acid receptor 1 (Gpbar1, TGR5) and the bile acid receptor FXR]; limits the autoimmune response
SCFA
Acetate and butyrateActs as histone deacetylase inhibitors; ameliorates inflammation
PropionateParticipates in carbohydrate esterification
ValericProvides calories; affects inflammation; enteroendocrine regulation through G-protein-coupled receptors (e.g., GPR41, GPR43)
IndolePromotes the function of the intestinal cell epithelial barrier; enhances the secretion of glucagon-like peptide-1 (GLP-1)
Endotoxins (LPS)Induces inflammation; limits the autoimmune response
H2SDestroys the intestinal barrier function
TMAInterferes with metabolism

Gpbar1 (TGR5): G-protein-coupled bile acid receptor 1; FXR: Farnesoid X receptor; SCFA: Short-chain fatty acid; GPR: G-protein-coupled receptors; GLP-1: Glucagon-like peptide-1; LPS: Lipopolysaccharide; H2S: Hydrogen sulfide; TMA: Trimethylamine.

Intestinal flora-related metabolites and their host interaction mechanism Gpbar1 (TGR5): G-protein-coupled bile acid receptor 1; FXR: Farnesoid X receptor; SCFA: Short-chain fatty acid; GPR: G-protein-coupled receptors; GLP-1: Glucagon-like peptide-1; LPS: Lipopolysaccharide; H2S: Hydrogen sulfide; TMA: Trimethylamine. Discovering the interactions of the intestinal microbiota under complex conditions, such as diet[46], drugs[47], genetic background of the host[48] and colonizing flora[49], modification of the intestinal flora through antibiotics[50-54], probiotics, prebiotics[55-57], and fecal microbiota transplantation, and causal relationships in people and precision treatment[58] will become more accessible using multi-omics. The potential of understanding the mechanisms of diabetes using multi-omics is tremendous. However, the systematic examination of T2DM-related colonic flora studies in therapeutic and clinical application must still be completed. An interesting example of fully understanding the mechanism of intestinal bacteria is Akkermansia muciniphila (A. muciniphila). A. muciniphila is a mucosal-dwelling anaerobe and the only known member of its genus. Animal and human data have indicated an inverse correlation between the intestinal abundance of A. muciniphila and obesity, dyslipidemia, and T2DM[59-61]. A. muciniphila supplementation restores epithelial mucosal integrity, reduces weight gain and fat accumulation, improves glucose tolerance, and reduces inflammation and metabolic endotoxemia in animal models. It may be a potential treatment for T2DM. However, A. muciniphila levels are increased in patients with Parkinson’s disease, multiple sclerosis, or Alzheimer’s disease[62-64], suggesting that this bacterium may have unforeseen harmful effects on the nervous system. Pure culture, sterilization, and component extraction can reduce this risk[65], which is consistent with the recently proposed concept of culturomics[66]. In short, through multi-omics it is likely that major breakthroughs in the study of the mechanism of T2DM-related intestinal flora perturbation will be made and that these breakthroughs will be gradually applied in the clinic.

MULTI-OMICS AND T2DM-RELATED DYSLIPIDEMIA

While intestinal flora disorder is a diet-related in vitro regulatory mechanism of T2DM, glucose and lipid metabolism disorders and insulin resistance are in vivo mechanisms[67]. In addition to glycomics[68,69], we want to emphasize the role of lipidomics in T2DM-related dyslipidemia. Dyslipidemia in T2DM, characterized by a high concentration of triglycerides, low concentration of high-density lipoprotein cholesterol, and increased concentration of small, dense low-density lipoprotein cholesterol particles, is associated with insulin resistance. It is also one of the major risk factors for cardiovascular disease in patients with diabetes[70]. Although active control of triglycerides and low-density lipoprotein cholesterol can delay the progression of T2DM and reduce the risk of adverse cardiovascular outcomes in patients, interventions to increase high-density lipoprotein cholesterol have had little success. Niacin was thought to raise high-density lipoprotein cholesterol and was used to control diabetic dyslipidemia previously. However, it was proven to be ineffective and removed from the treatment guidelines[71-75]. Lipidomics, the systematic analysis of lipid composition and expression changes, can intensify the understanding of lipid metabolism alterations in T2DM. Recent population lipidomics data revealed that the T2DM-related lipid profile included decreased lysophospholipids, phosphatidylcholines, sphingomyelins, and cholesterol esters and increased triacylglycerols, diacylglycerols, and phosphatidylethanolamines[76-78]. Although these indicators can be used as potential biomarkers to predict the risk of T2DM, its prediction for a particular disease has not yet been verified. Balgoma et al[79] compared the lipid profiles from patients with non-alcoholic fatty liver disease, cardiovascular incidents, hepatocellular carcinoma, and T2DM. They noted that the upregulation of triacylglycerols, palmitic acid, palmitoleic acid, stearic acid and oleic acid is a fingerprint of liver X receptor-mediated lipogenesis in the liver. To thoroughly understand the mechanisms of T2DM-related lipid metabolism disorders, the utilization of lipidomics, and the integration of databases will undoubtedly achieve this goal.

CONCLUSION

Multi-omic studies have provided new breakthroughs and directions to guide traditional molecular biology research. The expansion of “omics” data and the continuous advancement of bioinformatics analysis technology will surely continue the advancement of our knowledge on the mechanisms of T2DM, especially on intestinal flora perturbation and dyslipidemia.

ACKNOWLEDGEMENTS

The authors want to thank Ms. Wang SE and Ms. Liu S for their suggestions and discussions during the writing process.
  79 in total

Review 1.  Proteomics, metabolomics and metagenomics for type 2 diabetes and its complications.

Authors:  Niannian Wang; Feifei Zhu; Liang Chen; Keping Chen
Journal:  Life Sci       Date:  2018-09-19       Impact factor: 5.037

Review 2.  Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition.

Authors:  William T Cefalu
Journal:  ILAR J       Date:  2006

3.  Good Bug, Bad Bug: Breaking through Microbial Stereotypes.

Authors:  Mihai Cirstea; Nina Radisavljevic; B Brett Finlay
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

4.  Human genetics shape the gut microbiome.

Authors:  Julia K Goodrich; Jillian L Waters; Angela C Poole; Jessica L Sutter; Omry Koren; Ran Blekhman; Michelle Beaumont; William Van Treuren; Rob Knight; Jordana T Bell; Timothy D Spector; Andrew G Clark; Ruth E Ley
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

Review 5.  Dyslipidemia in type 2 diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

6.  A G protein-coupled receptor responsive to bile acids.

Authors:  Yuji Kawamata; Ryo Fujii; Masaki Hosoya; Masataka Harada; Hiromi Yoshida; Masanori Miwa; Shoji Fukusumi; Yugo Habata; Takashi Itoh; Yasushi Shintani; Shuji Hinuma; Yukio Fujisawa; Masahiko Fujino
Journal:  J Biol Chem       Date:  2003-01-10       Impact factor: 5.157

7.  Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy.

Authors:  Rosina Pryor; Povilas Norvaisas; Georgios Marinos; Lena Best; Louise B Thingholm; Leonor M Quintaneiro; Wouter De Haes; Daniela Esser; Silvio Waschina; Celia Lujan; Reuben L Smith; Timothy A Scott; Daniel Martinez-Martinez; Orla Woodward; Kevin Bryson; Matthias Laudes; Wolfgang Lieb; Riekelt H Houtkooper; Andre Franke; Liesbet Temmerman; Ivana Bjedov; Helena M Cochemé; Christoph Kaleta; Filipe Cabreiro
Journal:  Cell       Date:  2019-08-29       Impact factor: 41.582

8.  Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice.

Authors:  Robert Caesar; Christopher S Reigstad; Helene Kling Bäckhed; Christoph Reinhardt; Maria Ketonen; Gunnel Östergren Lundén; Patrice D Cani; Fredrik Bäckhed
Journal:  Gut       Date:  2012-04-25       Impact factor: 23.059

9.  Bacterial colonization factors control specificity and stability of the gut microbiota.

Authors:  S Melanie Lee; Gregory P Donaldson; Zbigniew Mikulski; Silva Boyajian; Klaus Ley; Sarkis K Mazmanian
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

View more
  4 in total

1.  The association between serum Sestrin2 and the risk of coronary heart disease in patients with type 2 diabetes mellitus.

Authors:  Xue Tian; Yu Gao; Min Zhong; Mowei Kong; Lihua Zhao; Zengbin Feng; Qitian Sun; Jianqiu He; Xiaoyan Liu
Journal:  BMC Cardiovasc Disord       Date:  2022-06-21       Impact factor: 2.174

Review 2.  Circulating microRNAs as predictive biomarkers of coronary artery diseases in type 2 diabetes patients.

Authors:  Golnoosh Mahjoob; Yasin Ahmadi; Huda Fatima Rajani; Nafiseh Khanbabaei; Sakhavat Abolhasani
Journal:  J Clin Lab Anal       Date:  2022-03-29       Impact factor: 3.124

3.  Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial.

Authors:  Jinghan Xu; Chunli Piao; Yue Qu; Tianjiao Liu; Yuting Peng; Qi Li; Xiaohua Zhao; Pei Li; Xuemin Wu; Yawen Fan; Binqin Chen; Jie Yang
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

4.  In silico functional and pathway analysis of risk genes and SNPs for type 2 diabetes in Asian population.

Authors:  Md Numan Islam; Md Golam Rabby; Md Munnaf Hossen; Md Mostafa Kamal; Md Ashrafuzzaman Zahid; Md Syduzzaman; Md Mahmudul Hasan
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.